Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Kuopio

173 clinical trials in Kuopio, Finland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Kuopio at a glance
173
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

173 trials in Kuopio

Open in trial search

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Gastrointestinal carcinoma

Recruiting

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Generalised anxiety disorder

Recruiting

Study on ITI-1284 for Patients with Generalized Anxiety Disorder Who Did Not Respond Well to Previous Treatments

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ITI-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Partial seizures

Recruiting

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Sjogren's syndrome

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Kuopio

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Innovative studies focusing on atherosclerotic cardiovascular disease and metabolic conditions. Research includes novel therapies for obesity management and cardiovascular risk reduction.

  • Weight Management Studies
  • Cardiovascular Prevention
  • Type 2 Diabetes Research

Multiple trials evaluating new therapeutic approaches for weight loss and cardiovascular health improvement.

02 Oncology Studies

Comprehensive research in various cancer types, including prostate cancer, breast cancer, and lymphomas. Focus on targeted therapies and treatment optimization.

  • Advanced Breast Cancer Treatments
  • Lymphoma Therapeutics
  • Renal Cell Carcinoma Research

Studies combining immunotherapy approaches with established treatments for better patient outcomes.

03 Inflammatory & Autoimmune Conditions

Research targeting various inflammatory conditions, including psoriatic arthritis and Sjögren's syndrome. Studies evaluating novel biological treatments.

  • Nasal Polyps Treatment
  • Autoimmune Disease Therapies
  • Inflammatory Conditions Management

Innovative approaches in treating chronic inflammatory and autoimmune disorders.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.